Bioanalysis · 2017 · 10 citations · 28 references
PharmacyPharmacologyForensic ToxicologyNeuropharmacologyPsychopharmacologyAdverse Drug Reaction DetectionNovel Psychoactive SubstancesAmphetamine DerivativesFree Drug SamplesIllicit Drug DetectionImmune Cross-reactivityImmunoassay Drug ScreeningImmunoassaysUrine Drug ScreeningUrine Toxicology Screening
AIM: The aim of this study was to perform a cross-reactivity investigation of six benzofurans with immunoassays (IAs) screening tests for amphetamines and ecstasy in urine samples. METHODS: The following benzofuranes were investigated: 5-(2-Methylaminopropyl)Benzofuran (5-MAPB), 5-(2-methylaminopropyl)-2,3-dihydrobenzofuran (5-MAPDB), 5-(2-Aminopropyl)-Benzofuran (5-APB), 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB), 5-(2-Ethylaminopropyl)Benzofuran (5-EAPB) and 5-(2-Aminoethyl)-2,3-dihydrobenzofuran (5-AEDB). The study was performed with urine-free spiked samples and authentic urine samples using eight different IAs for amphetamines and ecstasy. Results: All evaluated benzofurans showed cross-reactivity in some of the IAs tested, except for 5-AEDB. Urine samples of an intoxication case involving 5-MAPB, 5-APB and 5-EAPB were also positives in the IAs tested. CONCLUSION: There is an important variability in the cross-reactivity of the IAs for amphetamine and ecstasy caused by benzofurans depending on the immunoassay employed and the tested compounds.
28
Neurochemical profiles of some novel psychoactive substances
Les Iversen, Simon Gibbons, Ric Treble et al. · European Journal of Pharmacology · 2012 · 170 citations · Full text
Medicine, Neuroscience, Pharmacology +11
Fabio Vaiano, Francesco Paolo Busardò, Diego Palumbo et al. · Journal of Pharmaceutical and Biomedical Analysis · 2016 · 117 citations